These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 38936744)

  • 1. Nanostructured lipid carriers promote percutaneous absorption and hair follicle targeting of tofacitinib for treating alopecia areata.
    Li Q; Wang Y; Guo Q; Cao J; Feng Y; Ke X
    J Control Release; 2024 Aug; 372():778-794. PubMed ID: 38936744
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Successful Treatment of Severe Alopecia Areata With Oral or Topical Tofacitinib.
    Cheng MW; Kehl A; Worswick S; Goh C
    J Drugs Dermatol; 2018 Jul; 17(7):800-803. PubMed ID: 30005104
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selective inhibition of JAK3 signaling is sufficient to reverse alopecia areata.
    Dai Z; Chen J; Chang Y; Christiano AM
    JCI Insight; 2021 Apr; 6(7):. PubMed ID: 33830087
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An Open-Label Pilot Study to Evaluate the Efficacy of Tofacitinib in Moderate to Severe Patch-Type Alopecia Areata, Totalis, and Universalis.
    Jabbari A; Sansaricq F; Cerise J; Chen JC; Bitterman A; Ulerio G; Borbon J; Clynes R; Christiano AM; Mackay-Wiggan J
    J Invest Dermatol; 2018 Jul; 138(7):1539-1545. PubMed ID: 29452121
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selective Delivery of Tofacitinib Citrate to Hair Follicles Using Lipid-Coated Calcium Carbonate Nanocarrier Controls Chemotherapy-Induced Alopecia Areata.
    Guan Y; Yan A; Qiang W; Ruan R; Yang C; Ma K; Sun H; Liu M; Zhu H
    Int J Mol Sci; 2023 May; 24(9):. PubMed ID: 37176141
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Squalene-containing nanostructured lipid carriers promote percutaneous absorption and hair follicle targeting of diphencyprone for treating alopecia areata.
    Lin YK; Al-Suwayeh SA; Leu YL; Shen FM; Fang JY
    Pharm Res; 2013 Feb; 30(2):435-46. PubMed ID: 23070602
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Janus Kinase Inhibitors for the Treatment of Severe Alopecia Areata: An Open-Label Comparative Study.
    Almutairi N; Nour TM; Hussain NH
    Dermatology; 2019; 235(2):130-136. PubMed ID: 30566941
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Case Report: Successful Treatment of Alopecia Universalis With Tofacitinib and Increased Cytokine Levels: Normal Therapeutic Reaction or Danger Signal?
    Yu L; Yu H; Zhang S; Hao Y; Zhang S
    Front Immunol; 2022; 13():904156. PubMed ID: 35795663
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Normalisation of hair follicle morphology in C3H/HeJ alopecia areata mice after treatment with squaric acid dibutylester.
    Gardner S; Freyschmidt-Paul P; Hoffmann R; Sundberg JP; Happle R; Lindsey NJ; Tobin DJ
    Eur J Dermatol; 2000 Aug; 10(6):443-50. PubMed ID: 10980465
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Successful treatment of alopecia areata-like hair loss with the contact sensitizer squaric acid dibutylester (SADBE) in C3H/HeJ mice.
    Freyschmidt-Paul P; Sundberg JP; Happle R; McElwee KJ; Metz S; Boggess D; Hoffmann R
    J Invest Dermatol; 1999 Jul; 113(1):61-8. PubMed ID: 10417620
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata.
    Kennedy Crispin M; Ko JM; Craiglow BG; Li S; Shankar G; Urban JR; Chen JC; Cerise JE; Jabbari A; Winge MC; Marinkovich MP; Christiano AM; Oro AE; King BA
    JCI Insight; 2016 Sep; 1(15):e89776. PubMed ID: 27699252
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systematic review - alopecia areata and tofacitinib in paediatric patients.
    Bandeira A; Albino-Teixeira A; Magina S
    Cutan Ocul Toxicol; 2022 Jun; 41(2):194-201. PubMed ID: 35687530
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of an alopecia areata patient with tofacitinib results in regrowth of hair and changes in serum and skin biomarkers.
    Jabbari A; Nguyen N; Cerise JE; Ulerio G; de Jong A; Clynes R; Christiano AM; Mackay-Wiggan J
    Exp Dermatol; 2016 Aug; 25(8):642-3. PubMed ID: 27119625
    [No Abstract]   [Full Text] [Related]  

  • 14. [Alopecia areata with good response to tofacitinib].
    Maksimow A; Stintzing D; Wohlrab J
    Hautarzt; 2021 Jun; 72(6):525-527. PubMed ID: 33044559
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nail involvement in patients with moderate-to-severe alopecia areata treated with oral tofacitinib.
    Lee JS; Huh CH; Kwon O; Yoon HS; Cho S; Park HS
    J Dermatolog Treat; 2018 Dec; 29(8):819-822. PubMed ID: 29658800
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tofacitinib as a treatment of alopecia areata in adolescents.
    Morales-Miranda AY; Bueno-Arias GM; Aguirre-Félix ÓG; Tovar-Franco R
    Bol Med Hosp Infant Mex; 2019; 76(4):182-187. PubMed ID: 31303654
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Janus kinase inhibitors for alopecia areata: A narrative review.
    Haughton RD; Herbert SM; Ji-Xu A; Downing L; Raychaudhuri SP; Maverakis E
    Indian J Dermatol Venereol Leprol; 2023; 89(6):799-806. PubMed ID: 37436019
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 2-deoxy D-glucose treatment does not elicit a hair growth response in alopecia areata.
    Sundberg JP; Silva KA; Kennedy VE; Wilson JJ; Gott NE; Sundberg BA; Roopenian DC
    Exp Dermatol; 2019 Sep; 28(9):1091-1093. PubMed ID: 31323149
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differences in activation of β-catenin in outer root sheath cells between the type of JAK inhibitor: An alternative mechanism promoting hair growth by JAK inhibitors in alopecia areata.
    Shin JM; Sung Y; Hong D; Jung KE; Seo YJ; Kim CD; Lee Y
    J Dermatol Sci; 2024 Jun; 114(3):148-150. PubMed ID: 38734548
    [No Abstract]   [Full Text] [Related]  

  • 20. Histological assessment of follicular delivery of flutamide by solid lipid nanoparticles: potential tool for the treatment of androgenic alopecia.
    Hamishehkar H; Ghanbarzadeh S; Sepehran S; Javadzadeh Y; Adib ZM; Kouhsoltani M
    Drug Dev Ind Pharm; 2016; 42(6):846-53. PubMed ID: 26154267
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.